Core Insights - Guangdong Taiankang Pharmaceutical Co., Ltd. has made significant progress in the innovative treatment of pediatric vitiligo with the acceptance of its clinical trial application for CKBA cream combined with narrowband ultraviolet B (NB-UVB) for children aged 2-12 [1][2] - The global prevalence of vitiligo, a chronic autoimmune disease characterized by skin pigment loss, is high, with children accounting for 32%-40% of cases, highlighting a substantial unmet clinical need in this demographic [1] Group 1 - The acceptance of the clinical trial application marks a key advancement for the company in the pediatric vitiligo treatment sector, potentially providing new options for affected children and their families [1] - Currently, there are no approved products for treating vitiligo in children globally, indicating a significant market opportunity for the company [1] - The company aims to address unmet clinical needs and enhance its innovative drug pipeline, reinforcing its commitment to public health and long-term value creation for investors [2] Group 2 - CKBA, a First-in-Class innovative drug with global intellectual property rights, is progressing steadily in its indication layout, with adult vitiligo in Phase II trials and plans for Phase III submission [2] - The company is also preparing for II/III phase trials for rosacea and advancing preclinical research for Alzheimer's disease, with an IND application planned for the second half of 2026 [2] - The acceptance of the pediatric vitiligo indication further enriches the company's indication matrix, showcasing its deep accumulation in innovative drug research and development [2]
泰恩康CKBA联合光疗早期研究疗效显著 临床申请获国家药监局受理